Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study

Autor: David Hagin, Emel Aygören-Pürsün, Aarnoud Huissoon, Olivier Fain, Marcus Maurer, Sorena Kiani-Alikhan, William P. Sheridan, Urs C. Steiner, Marcin Stobiecki, Adrian Wu, Melanie Cornpropst, Bhavisha Desai, Avner Reshef, Sylvia Dobo, Celia Zubrinich, Anette Bygum, Henriette Farkas, Jonny Peter, Eniko Nagy, Heather Iocca, Jessica M. Best, Daniel Dix, Vesna Grivcheva Panovska, Tamar Kinaciyan, S. Murray, Miloš Jeseňák, Karen Lindsay

Publikováno v: Clinical and Translational Allergy, Vol 11, Iss 4, Pp n/a-n/a (2021)
Clinical and Translational Allergy
Farkas, H, Stobiecki, M, Peter, J, Kinaciyan, T, Maurer, M, Aygören-Pürsün, E, Kiani-Alikhan, S, Wu, A, Reshef, A, Bygum, A, Fain, O, Hagin, D, Huissoon, A, Jeseňák, M, Lindsay, K, Panovska, V G, Steiner, U C, Zubrinich, C, Best, J M, Cornpropst, M, Dix, D, Dobo, S M, Iocca, H A, Desai, B, Murray, S C, Nagy, E & Sheridan, W P 2021, ' Long-term safety and effectiveness of berotralstat for hereditary angioedema : The open-label APeX-S study ', Clinical and Translational Allergy, vol. 11, no. 4, e12035 . https://doi.org/10.1002/clt2.12035
Clinical and Translational Allergy, BioMed Central, 2021, 11 (4), ⟨10.1002/clt2.12035⟩

Background: Berotralstat (BCX7353) is an oral, once-daily inhibitor of plasma kallikrein recently approved for prevention of angioedema attacks in adults and adolescents with hereditary angioedema (HAE). The objective of this report is to summarize r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e81f42d82c32ab05143c0be9d9ea1878
https://doi.org/10.1002/clt2.12035

Reduction in Attacks in Hereditary Angioedema (HAE) With Berotralstat is Consistent Regardless of Prior Prophylactic Treatment: A Subgroup Analysis of the Phase 3 APeX-2 Trial

Autor: Jessica M. Best, Heather Iocca, John Anderson, Remi Gagnon, S. Murray, Karl Sitz

Publikováno v: Journal of Allergy and Clinical Immunology. 147:AB23

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::eff045ee4914002795664bd6df1991b0
https://doi.org/10.1016/j.jaci.2020.12.122

Berotralstat Consistently Demonstrates Reductions in Attack Frequency in Hereditary Angioedema (HAE) Irrespective of Baseline Attack Rate: Subgroup Analysis from the APeX-2 Trial

Autor: S. Murray, Heather Iocca, H. Henry Li, Raffi Tachdijan, Jessica M. Best

Publikováno v: Journal of Allergy and Clinical Immunology. 147:AB22

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::607a723d19baaff03f62a06ffa3d1d3d
https://doi.org/10.1016/j.jaci.2020.12.118

Gastrointestinal (GI) Adverse Events (AEs) Observed With Berotralstat (BCX7353) Treatment for Hereditary Angioedema (HAE) are Primarily Mild, Self-limited, and Diminish with Time on Treatment

Autor: Marco Cicardi, Eniko Nagy, Sylvia Dobo, William P. Sheridan, Douglas T. Johnston, Jonathan A. Bernstein, Marc A. Riedl, Sandra C. Christiansen, Philip Collis, Heather Iocca, Bruce L. Zuraw, Paula J. Busse, Marcus Maurer, S. Murray, Aleena Banerji, William R. Lumry, Melanie Cornpropst, Emel Aygören-Pürsün, Huamin Li

Publikováno v: Journal of Allergy and Clinical Immunology. 145:AB102

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c73c3f4688151656d138b0ab5f0dde51
https://doi.org/10.1016/j.jaci.2019.12.619